A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects with Advanced Breast Cancer
The purpose of this research study is to test the safety of a drug called Seviteronel. Seviteronel is an oral drug that may block the growth of cancer cells in multiple types of breast cancer.
Group 1: Female patients with AR+ triple negative breast cancer “Triple negative” means that your breast cancer is negative for estrogen, progesterone, and Human Epidermal growth factor (HER2) Receptors. AR+ means that your cancer has tested positive for the androgen receptor
Group 2: Female ER (+) breast cancer patients. ER+ means that your breast cancer is positive for estrogen receptors
Group 3: Male patients with breast cancer
1. Male or female age 18 or older
2. Confirmed invasive breast cancer
18 - 100
Healthy Volunteers Needed
Duration of Participation
This study will take place over about 24 months. Study treatment will continue until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be contacted by phone every 12 weeks until the end of the study.
Knight Clinical Trials Information Line
Innocrin Pharmaceuticals, Inc.